TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)

• Main Authors: K. I. Zarubina, E. N. Parovichnikova, O. A. Gavrilina, A. N. Sokolov, V. V. Troitskaya, L. A. Kuzmina, V. E. Mamonov, G. M. Galstyan, V. G. Savchenko
• Format: Article
• Language: Russian
• Published: ABV-press 2017-10-01
• Series: Onkogematologiâ
• Subjects: ph-positive acute lymphoblastic leukemia; tyrosine kinase inhibitors; selectivity; combined toxicity; t315i mutation; imatinib; nilotinib; dasatinib; axitinib; ponatinib; blinatumomab
• Online Access: https://oncohematology.abvpress.ru/ongm/article/view/257

A wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cytotoxic drugs, enhancing myelotoxicity and, as a consequence, infections and thrombo-hemorrhagic complications. In addition, complex inter-drug interactions lead to the manifestations of combined toxicity. This article presents a case report of patient with relapsed acute Ph-positive lymphoblastic leukemia, treatment of which was accompanied by numerous complications, especially during treatment of II and III generation tyrosine kinases inhibitors.